SEC Company Response from Coherus Oncology, (CHRS) — Dec 5, 2025
Coherus Oncology, Inc.
Date: Dec. 5, 2025 · CIK: 0001512762 · Accession: 0001104659-25-118941
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-291520
Letter
Coherus Oncology, Inc.
333 Twin Dolphin Drive, Suite 600
Redwood City, CA 94065
December 5, 2025
VIA EDGAR
United States Securities and Exchange Commission
Division of Corporation Finance
100 F Street, NE
Washington, D.C. 20549
Re: Coherus Oncology, Inc.
Registration Statement on Form S-3
(File No. 333-291520)
Ladies and Gentlemen:
In accordance with Rule 461 of the General Rules and Regulations under the Securities Act of 1933, as amended, Coherus Oncology, Inc. (the " Company ") hereby requests acceleration of the effective date of its Registration Statement on Form S-3 initially filed on November 13, 2025 (the " Registration Statement "). The Company respectfully requests that the Registration Statement become effective as of 4:30 p.m., Eastern Time, on December 8, 2025, or as soon thereafter as practicable. Once the Registration Statement has been declared effective, please orally confirm that event with the Company's counsel, Latham & Watkins LLP, by calling Drew Capurro at (714) 755-8008.
Very truly yours,
Coherus Oncology, Inc.
Show Raw Text
CORRESP 1 filename1.htm Coherus Oncology, Inc. 333 Twin Dolphin Drive, Suite 600 Redwood City, CA 94065 December 5, 2025 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, NE Washington, D.C. 20549 Re: Coherus Oncology, Inc. Registration Statement on Form S-3 (File No. 333-291520) Ladies and Gentlemen: In accordance with Rule 461 of the General Rules and Regulations under the Securities Act of 1933, as amended, Coherus Oncology, Inc. (the " Company ") hereby requests acceleration of the effective date of its Registration Statement on Form S-3 initially filed on November 13, 2025 (the " Registration Statement "). The Company respectfully requests that the Registration Statement become effective as of 4:30 p.m., Eastern Time, on December 8, 2025, or as soon thereafter as practicable. Once the Registration Statement has been declared effective, please orally confirm that event with the Company's counsel, Latham & Watkins LLP, by calling Drew Capurro at (714) 755-8008. Very truly yours, Coherus Oncology, Inc. By: /s/ Bryan McMichael Name: Bryan McMichael Title: Chief Financial Officer cc: Dennis M. Lanfear, Coherus Oncology, Inc. Benjamin A. Potter, Latham & Watkins LLP Drew Capurro, Latham & Watkins LLP